NVAX

Business Context and Reporting Period

Company: Novavax, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006

Novavax is a biopharmaceutical company that transitioned in 2005 from a specialty pharmaceutical firm to a vaccine-focused entity. Its core strategy leverages proprietary Virus-Like Particle (VLP) technology to develop vaccines for pandemic and seasonal influenza, HIV/AIDS, and other infectious diseases. The company also utilizes Micellar Nanoparticle (MNP) technology for drug delivery, primarily through its FDA-approved product ESTRASORB, which is licensed for North American marketing to Esprit Pharma, Inc.

Key Financial Metrics

Cash Flow Summary (2006):

• Operating Activities: $(14.8) million used
• Investing Activities: $(66.8) million used (primarily short-term investment purchases)
• Financing Activities: $56.9 million provided (primarily equity offerings)

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 37% to $4.7 million. This was driven by the divestiture of vitamin and AVC product lines in 2005 and the licensing of ESTRASORB marketing rights to Esprit, which reduced direct product sales. Product sales dropped from $4.5 million in 2005 to $2.5 million in 2006.
• Increased Net Loss: Net loss widened to $23.1 million from $11.2 million. The 2005 period included a one-time $11.0 million gain on the sale of product assets (ESTRASORB license and Pharmelle transaction), which was absent in 2006.
• R&D Surge: Research and development expenses increased 127% to $11.5 million, reflecting a strategic shift to accelerate VLP vaccine development for influenza and HIV.
• Selling & Marketing Reduction: Expenses plummeted 99% to $0.1 million following the elimination of the internal sales force in 2005 to align with the licensing strategy.
• Capital Position: Cash and investments more than doubled to $73.6 million due to two significant equity offerings in early 2006 raising approximately $58 million in gross proceeds.

Guidance, Outlook, and Risks

Outlook and Strategy:

• Management anticipates initiating human clinical trials for its pandemic influenza vaccine by mid-2007 and seasonal influenza vaccine trials in the first half of 2008.
• The company expects to continue incurring significant operating losses as it funds clinical trials, expands manufacturing capacity, and protects its intellectual property.
• Management believes current capital resources are sufficient to fund operations into the second half of 2008, absent new financings or redemptions of convertible notes.

Risks and Contingencies:

• Profitability: The company has a history of losses with an accumulated deficit of $165 million. There is no assurance it will achieve profitability.
• Manufacturing Losses: The company currently manufactures ESTRASORB at a loss because production costs exceed the fixed price paid by Esprit. This loss is expected to continue until production volumes increase or additional contract manufacturing agreements are secured.
• Convertible Debt: $22 million in senior convertible notes (4.75% coupon) are outstanding, maturing in 2009. Note holders have redemption rights if the stock price remains below the conversion price ($5.46) for specific periods in 2007 or 2008.
• Related Party Transactions: The company has outstanding promissory notes to directors totaling approximately $1.0 million, which may be viewed negatively by the market.
• Regulatory Approval: Success depends on obtaining FDA approval for vaccine candidates, a process that is costly, time-consuming, and uncertain.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $73.6 million cash balance against the projected $14.8 million annual operating cash burn and upcoming clinical trial costs.
• Convertible Note Redemption Risk: Monitor the stock price relative to the $5.46 conversion price to assess the risk of forced redemption of the $22 million debt in 2007 or 2008.
• ESTRASORB Economics: Confirm the timeline for resolving the manufacturing loss on ESTRASORB and the status of negotiations for packaging and lease cost revisions.
• Clinical Trial Milestones: Track the initiation of Phase I/II clinical trials for the pandemic influenza vaccine (targeted mid-2007) as a key value driver.
• Equity Dilution: Assess the impact of potential future equity financings required to fund operations beyond 2008.